Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¼º»ó±³¼¼Æ÷Á¾¿¡¼­ p53 À¯ÀüÀÚÀÇ µ¹¿¬º¯ÀÌ -Á÷Á¢¿°±â¼­¿­ °áÁ¤¹ý¿¡ ÀÇÇÑ °Ë»ö- p53 Gene Mutations in Astrocytoma -Detection by Direct DNA Sequencing-

´ëÇѾÏÇÐȸÁö 1997³â 29±Ç 4È£ p.590 ~ 598
ÃÖ¿øÈñ, Àå¿ìÇö, ÃÖ°æÂù,
¼Ò¼Ó »ó¼¼Á¤º¸
ÃÖ¿øÈñ (  ) 
¿µ³²´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç

Àå¿ìÇö (  ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
ÃÖ°æÂù (  ) 
ÇѸ²´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç

Abstract

°á·Ð
³úÁ¾¾ç¿¡¼­µµ p53 À¯ÀüÀÚÀÇ µ¹¿¬º¯ÀÌ°¡ º¸°íµÈ ÀÌ·¡·Î ½Å°æ±³Á¾ÀÇ ÁøÇà¿¡ Áß¿äÇÑ ¿ªÇÒÀ»
ÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖÀ¸³ª, ½Å¼± µ¿°áÁ¶Á÷À» ÀÌ¿ëÇÑ ½ÇÇèÀ¸·Î´Â ¿©·¯ °¡Áö Á¦ÇÑÀûÀ̾ú´Ù.
ÀÌ¿¡ ÀúÀÚ´Â Æ÷¸£¸»¸°¿¡ °íÁ¤µÈ 10 ¥ìm µÎ²²ÀÇ ÆĶóÇÉ Æ÷¸ÅÁ¶Á÷À» ÀÌ¿ëÇÏ¿© PCR°ú Á÷Á¢¿°
±â¼­¿­ °áÁ¤¹ýÀ¸·Î exon 5¡­8¹ø ºÎÀ§¿¡¼­ p53 À¯ÀüÀÚÀÇ µ¹¿¬º¯À̸¦ °Ë»öÇÏ¿´´Ù.
½ÇÇ豺À¸·Î´Â Á¶Á÷»ý°ËÀ¸·Î Áø´ÜµÈ ³úÀÇ ½Å°æ±³¼¼Æ÷Á¾ Áß Àß º¸Á¸µÈ ÆĶóÇÉ ºí·Ï 20¿¹¸¦
´ë»óÀ¸·Î ÇÏ¿©, ¼º»ó±³¼¼Æ÷Á¾ 10¿¹¿Í ¿ªÇü¼º ¼º»ó±³¼¼Æ÷Á¾ 10¿¹·Î ÇÏ¿´´Ù. Á¤»ó´ëÁ¶±ºÀ¸·Î´Â
¿ÜÀμº ºÎ°ËȯÀÚ Áß Á¤»ó ³úÁ¶Á÷ ¼Ò°ßÀ» º¸ÀÎ 10¿¹·Î ÇÏ¿© ´ÙÀ½°ú °°Àº °á°ú¸¦ ¾ò¾ú´Ù.
p53 À¯ÀüÀÚÀÇ µ¹¿¬º¯ÀÌ´Â ¿ªÇü¼º ¼º»ó±³¼¼Æ÷Á¾ 10¿¹ Áß 1¿¹(10%)¿¡¼­ È®ÀεǾú´Ù. Áï, ¿ª
Çü¼º ¼º»ó±³¼¼Æ÷Á¾¿¡¼­´Â 2¹ø ¿¹ÀÇ exon 7¹ø¿¡¼­ ÄÚµ· 245¹øÀÌ GGC¡æGAC(Gly¡æAsp)·Î
Á¡µ¹¿¬º¯À̸¦ º¸¿´´Ù. ¾ç¼ºÀÇ ¼º»ó±³¼¼Æ÷Á¾ 10¿¹¿Í Á¤»ó´ëÁ¶±º 10¿¹¿¡¼­´Â p53À¯ÀüÀÚÀÇ µ¹
¿¬º¯ÀÌ°¡ °Ë»öµÇÁö ¾Ê¾Ò´Ù.
ÀÌ»óÀÇ °á°ú¸¦ Á¾ÇÕÇϸé ÆĶóÇÉ Æ÷¸ÅÁ¶Á÷À» ÀÌ¿ëÇÔÀ¸·Î½á ´Ù¾çÇÑ ¾ÏÁ¾¿¡¼­ p53 À¯ÀüÀÚÀÇ
µ¹¿¬º¯ÀÌ¿¡ ´ëÇÑ ¿¬±¸°¡ °¡´ÉÇÏ°Ô µÇ¾ú°í, º» ¿¬±¸¿¡¼­ ÀÌ¿ëÇÑ PCR ¹× Á÷Á¢¿°±â¼­¿­ °áÁ¤
¹ýÀÌ À¯¿ëÇÑ ¹æ¹ýÀ¸·Î »ç·áµÈ´Ù. ÇâÈÄ ´õ ¸¹Àº ¿¹ÀÇ ¿ªÇü¼º ¼º»ó±³¼¼Æ÷Á¾ ¹× ±³¸ð¼¼Æ÷Á¾¿¡
¼­ p53 À¯ÀüÀÚÀÇ µ¹¿¬º¯ÀÌ¿¡ ´ëÇÑ °Ë»öÀ» ÅëÇØ, ¾ç¼º ¼º»ó±³¼¼Æ÷Á¾ÀÌ ¾Ç¼ºÀ¸·ÎÀÇ ÀÌÇà ½Ã
p53 À¯ÀüÀÚÀÇ ¿ªÇÒÀ» ±Ô¸íÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î »ç·áµÈ´Ù.
#ÃÊ·Ï#
Purpose: Mutations in the p53 gene have been recognized in brain tumor, and clonal
expansion of p53 mutant cells has been shown to be associated with glioma progression.
However, studies on the p53 gene have been limited by the need for fresh frozen
tissues. We have tried a method utilizing polymerase chain reaction(PCR) for the direct
DNA sequencing of the p53 gene using a single 10¥ìm paraffin-embedded tissue section.
We applied this method to detect for p53 gene mutations in exons 5¡­8 in human
astrocytoma utilizing paraffin-embedded tissues.
Materials and Methods: Twenty paraffin blocks containing tumor were selected from
surgical specimens from twenty different cases. Tumors included 10 astrocytomas and
10 anaplastic astrocytomas. Ten controls were also selected among autopsy cases
showing normal brain in light microscopy. The tissue section on the stained glass slide
was used to guide microdissection of an unstained adjacent tissue section to ensure
above 90% of the tumor cell population for p53 mutational analysis.
Result: Mutation in the p53 gene was identified in 1 of 10(10%) anaplastic
astrocytomas. Mutations in the p53 gene were identified in 1 of 10 cases(10%) by PCR
and direct DNA sequencing. Mutation in exon 7 resulting in amino acid substitution was
found in one anaplastic astrocytoma(codon 245, GGC¡æGAC: glycine¡æaspartic acid). Ten
control cases, ten astrocytomas and nine anaplastic astrocytomas were confirmed to be
negative by direct sequencing of amplified DNA.
Conclusion: This study demonstrates the feasibility of evaluating p53 gene mutations
in archived astrocytoma specimens using PCR and direct DNA sequencing on paraffin
sections. Application of this method should facilitate investigation of the role of p53 gene
mutations in tumor biology.

Å°¿öµå

Anaplastic astrocytoma; p53; Gene mutation; PCR; Direct DNA sequencing;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS